Department of Radiology
Found 15 results
Filters: Keyword is Radioisotopes  [Clear All Filters]
2023
Chung SK, Vargas DBurnes, Chandler CS, Katugampola S, Veach DR, McDevitt MR, Seo SH, Vaughn BA, Rinne SS, Punzalan B et al..  2023.  Efficacy of HER2-Targeted Intraperitoneal 225Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis.. J Nucl Med. 64(9):1439-1445.
Kurtz K, Eibler L, Dacek MM, Carter LM, Veach DR, Lovibond S, Reynaud E, Qureshy S, McDevitt MR, Bourne C et al..  2023.  Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.. Theranostics. 13(15):5469-5482.
Stangl-Kremser J, Ricaurte-Fajardo A, Subramanian K, Osborne JR, Sun M, Tagawa ST, Bander NH.  2023.  Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.. Prostate. 83(10):901-911.
Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, Koo PJ, Morgans AK, Osborne JR, Tagawa ST et al..  2023.  SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy.. J Nucl Med. 64(9):1417-1423.
2022
Lawhn-Heath C, Hope TA, Martinez J, Fung EK, Shin J, Seo Y, Flavell RR.  2022.  Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose.. Lancet Oncol. 23(2):e75-e87.
2020
Bellat V, Alcaina Y, Tung C-H, Ting R, Michel AO, Souweidane M, Law B.  2020.  A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment.. Neuro Oncol. 22(10):1495-1504.
Deh K, Zaman M, Vedvyas Y, Liu Z, Gillen KMcCabe, Malley PO', Bedretdinova D, Nguyen T, Lee R, Spincemaille P et al..  2020.  Validation of MRI quantitative susceptibility mapping of superparamagnetic iron oxide nanoparticles for hyperthermia applications in live subjects.. Sci Rep. 10(1):1171.
2019
Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, Cheal SM, O'Donoghue JA, Ruan S, Ragupathi G et al..  2019.  Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.. J Nucl Med. 60(11):1517-1523.
O'Donoghue JA, Danila DC, Pandit-Taskar N, Beylergil V, Cheal SM, Fleming SE, Fox JJ, Ruan S, Zanzonico PB, Ragupathi G et al..  2019.  Pharmacokinetics and Biodistribution of a [Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.. Mol Pharm. 16(7):3083-3090.
2017
Kelly JM, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C, Vallabhajosula S, Babich JW.  2017.  Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of Ga, In, Lu and Ac.. Nucl Med Biol. 55:38-46.
2014
Doran MG, Watson PA, Cheal SM, Spratt DE, Wongvipat J, Steckler JM, Carrasquillo JA, Evans MJ, Lewis JS.  2014.  Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.. J Nucl Med. 55(12):2045-9.
Cheal SM, Yoo B, Boughdad S, Punzalan B, Yang G, Dilhas A, Torchon G, Pu J, Axworthy DB, Zanzonico P et al..  2014.  Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy.. Mol Pharm. 11(2):400-16.
Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gönen M et al..  2014.  ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.. Eur J Nucl Med Mol Imaging. 41(11):2093-105.
2013
Efthimiou N, Loudos G, Karakatsanis NA, Panayiotakis GS.  2013.  Effect of 176Lu intrinsic radioactivity on dual head PET system imaging and data acquisition, simulation, and experimental measurements.. Med Phys. 40(11):112505.
Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL, Lewis JS.  2013.  Imaging tumor burden in the brain with 89Zr-transferrin.. J Nucl Med. 54(1):90-5.